INTRODUCTION
Upper urinary tract urothelial carcinoma (UTUC) is a rare malignancy, accounting for 5% of urothelial tumors. 1 The gold standard management for non-metastatic UTUC is radical nephrouretectomy with bladder cuff excision. 2 Nephron-sparing procedures, including segmental ureterectomy and endoscopic ablation or resection, are often employed in select patients. 3 Postoperative recurrences are common. The primary aims of postoperative surveillance for UTUC are to identify urothelial recurrences, de novo tumours of the urinary tract, and distant metastases at early stages when they may be amenable to treatment. The rarity of the disease, as well as the heterogeneity of treatments, complicates the task of developing a standard follow-up protocol.
Multiple studies report on postoperative recurrence and prognosis for UTUC. By performing a systematic literature review, we generated an evidence-based consensus protocol for the surveillance of patients after surgery for UTUC based on the predictors, timing, and locations of recurrences reported in the literature. The decision to provide neoadjuvant or adjuvant treatments is beyond the scope of this guideline and will not be reviewed. Wherever possible, the levels of evidence and grades of recommendation are noted using the modified Oxford Centre for Evidence-based Medicine system.
METHODS
A systematic literature review of the electronic databases Embase, Medline, and Cochrane was performed using the following search terms, their synonyms, related terms, and relevant exploded terms: upper tract, urothelial carcinoma, transitional cell carcinoma, nephrouretectomy, ureterectomy, endoscopy, ureteroscopy, nephroscopy, percutaneous, follow-up, surveillance, recurrence, outcomes, and prognosis. No language restrictions were implemented. Citations from included articles and review articles were manually searched.
The inclusion and exclusion criteria were defined a priori. Studies which reported rates and/or patterns of recurrence after surgery (nephroureterectomy or nephronsparing procedures) for UTUC were included. Nephron-sparing procedures include segmental ureterectomy and endoscopic (retrograde or antegrade) ablation or resection. Non-observational studies were excluded. No sample size limitations were applied to prospective studies. For retrospective studies, minimum sample sizes for nephroureterectomy series and nephron-sparing series were 100 and 20 respectively, with exceptions for special reasons by author consensus and with explanation. When multiple studies reporting on the same patient population were identified, we attempted to include only the most relevant study. Studies with major design flaws were excluded by author consensus and with explanation. For recurrence/metastases rates, weighted means across all relevant studies were calculated when possible; these are reported as "mean (range of means)". Where applicable, the weighted mean of follow-up duration is also included within parentheses.
RESULTS
Fifty-nine studies satisfied the inclusion criteria of which 33 pertained to nephroureterectomy and 26 to nephron-sparing procedures. The results of the search strategy are shown in Figure 1 . One prospective study was included; 26 the rest are retrospective case-series, including several large multi-centre series.
One retrospective study of patients after nephroureterectomy with a sample size < 100 was included by author consensus because of its large sample of pT3 tumours. 27 No studies were excluded for major design flaws. In virtually all series, formal lymphadenectomy was not performed and methods of bladder cuff excision were not standardized. All studies report relatively high rates of postoperative recurrence.
Prognostic variables
Many studies report variables which are predictive of post-nephroureterectomy recurrence on multivariate analyses. The most commonly cited variable is tumour stage. In a retrospective series of 301 patients who underwent nephroureterectomy, Li et al. reported 5-year recurrence-free survival for patients with pTa/pTis/pT1, pT2, pT3, and pT4 tumours of 76.6%, 65.4%, 41.2%, and 0%, respectively. 16 In a large retrospective multicentre series of 1363 patients, Margulis et al. reported 5-year extravesical recurrence-free survival for pTa/pTis, pT1, pT2, pT3, and pT4 tumours of 91.8%, 88%, 71%, 48%, and 4.7%, respectively. 19 Additionally, tumour grade is associated with oncologic outcomes. While there is correlation between stage and grade, 44, 63 each independently predicts postoperative recurrence. 19 Although lymphadenectomy is seldom performed for clinically node-negative disease, 64 pathologic lymph node status is a strong predictor of postnephroureterectomy recurrence. 19, 21 Among 1363 patients, those with pathologically positive lymph nodes (N+) had 5-year recurrence-free survival of 29% compared to 73% in patients with negative (N0) or unknown (Nx) lymph node status. 19 In a large retrospective multicentre Canadian series, 5-year overall survival rates for Nx, N0, and N+ patients were 66.1%, 66.0% and 29.8% respectively. 31 Other prognostic variables following nephroureterectomy include lymphovascular invasion, concomitant carcinoma in situ (CIS), positive surgical margins, ureteral tumour location (as opposed to renal pelvis), previous or concomitant bladder tumours, tumour multifocality, and lack of postoperative intravesical mitomycin C instillation. 4, 6, 7, 10-12, 14-19, 21-24, 26, 28-36, 65-69 The rates of recurrence stratified by these variables are seldom reported.
Owing to the small sample sizes of most studies, multivariate analyses examining the predictors of recurrence after nephron-sparing procedures are lacking. Tumour grade is associated with recurrence; in a retrospective series of 40 patients, 75% of patients with high grade disease had recurrence by 2 months and ultimately underwent nephroureterectomy. 43 Similarly, among 60 patients with a mean follow-up of 51 months, disease-specific survival for patients with grades 1, 2, and 3 tumours was 100%, 94%, and 62%, respectively. 54 Additionally, tumour stage and multifocality correlate with recurrence after nephron-sparing procedures. 44, 47, 52, 56 Due to a lack of adequately powered studies, additional prognostic factors following nephron-sparing procedures are presently unknown.
Bladder recurrences
Among all patients with available data, bladder recurrences occurred following nephroureterectomy in 29.0% (22-47%; 35.9 months). In a retrospective series of 422 patients, Kim et al. reported median times to bladder recurrence and muscleinvasive bladder cancer of 8 and 17 months respectively. 34 The median reported time to bladder recurrence across all studies was 6-12 months. Bladder recurrences were noted as early as one month post-nephroureterectomy.
Following nephron-sparing procedures, bladder recurrences occurred in approximately 34% of patients. 70 In a retrospective series of 30 patients, the mean time to recurrence was 7 months and ranged from 6 to 72 months. 52 
Extravesical recurrences
Across all studies, post-nephroureterectomy recurrences of the retroperitoneum or pelvis occurred in a mean 4.6% (0-12%; 32.7 months). UTUC of the contralateral upper tract occurred in a mean 2.2% (0-4.6%; 46.7 months). Several studies report very low incidences of port-site recurrences, usually associated with inadvertent entry into the collecting system. 10 The recommended protocol for postoperative surveillance of UTUC is shown in Table 1 . Routine blood work should include renal function tests and a metabolic panel including liver function tests, calcium, and alkaline phosphatase. Although other published guidelines have recommended cystoscopy and urine cytology at 3 months then yearly after nephroureterectomy, 2 we advocate a more aggressive surveillance protocol given the high rates of urothelial recurrences in all patients and the reported median time to bladder recurrence of 6-12 months. Thus, the bladder should be assessed with cytology and cystoscopy in all patients at months 3, 6, 12, 18, 24, and annually thereafter up to 10 years of recurrence-free survival.
(Grade C).
The majority of patients following nephron-sparing procedures will develop ipsilateral upper tract recurrences. Computed tomography urography (CTU) lacks sensitivity to identify up to 75% of these recurrences. 56 Furthermore, the sensitivity of ureteroscopy with selective cytology or biopsy is superior to retrograde pyelography alone. 71 The ipsilateral upper tract should therefore be assessed by ureteroscopy and selective cytology or biopsy in all patients following nephronsparing procedures at months 3, 6, 12, 18, 24, and annually thereafter up to 10 years of recurrence-free survival. (Grade C)
To assess for local, contralateral, and distant metastases in patients after nephroureterectomy or nephron-sparing procedures, imaging of the abdomen and pelvis with computed tomography urography (CTU) is recommended (Grade C). 
Surveillance for any grade pT>2 or pN+ patients
History, physical examination, blood work, urine cytology, and cystoscopy should be performed at months 3, 6, 12, 18, 24 and annually thereafter (Grade C). CXR and CTU should be performed at months 3, 6, 12, 18, 24, 30, 36, and annually thereafter (Grade C). Following nephron-sparing procedures, ipsilateral ureteroscopy with selective cytology or biopsy should be performed at months 3, 6, 12, 18, 24, and annually thereafter (Grade C). Cystoscopy and ureteroscopy may be omitted from the surveillance protocol after ten 10 years of recurrence-free survival (Grade D). 
TABLES AND FIGURES
LG pT2 Nx/0 HG pT<2 Nx/0 or Hx and PE
LG/HG pT>2 or pN+ Hx and PE
LG: low grade; HG: high grade; Hx: History; PE: physical examination; CXR: chest x ray; CTU: computed tomography urography; pT<2 includes pTis, pTa and pT1; *Ipsilateral ureteroscopy with selective cytology or biopsy should be performed following nephron-sparing procedures 
